Skip to Content

Department of Translational Molecular Pathology

The Department of Translational Molecular Pathology under the direction of Ignacio I. Wistuba, M.D., Professor and Chair is initiating a thematic change that will expand translational research. As MD Anderson moves toward molecular characterization of the cancers of all our patients, allowing their optimal assignments to promising new targeted therapies and potential identification of biomarkers of response and resistance, the department’s mission includes thematic translational research and preclinical molecular pathology research.

The mission of Translational Molecular Pathology is focused on three goals: 1) the discovery of novel molecular targets for chemoprevention and treatment, 2) the development and validation of biomarkers for diagnosis and prediction of response/resistance to treatment, and 3) the transition of assays developed in the department into the CLIA environment. These goals will be achieved through collaboration with faculty from MDL and other laboratories, and participation in both the new clinical test evaluation process overseen by the virtual Molecular Targets and Markers Testing Facility, and in the division’s clinical laboratory test governance. CLIA-accredited testing will remain in division’s clinical laboratories.


© 2014 The University of Texas MD Anderson Cancer Center